Cocrystal Pharma (8CC) Stock Price & Analysis
8CC Stock Chart & Stats
- Day’s Range
- EUR 0.87 - EUR 0.87
- 52-Week Range
- EUR 0.69 - EUR 1.30
- Previous Close
- EUR 0.84
- Volume
- N/A
- Average Volume (3M)
- 6
- Market Cap
- EUR 18.17M
- Enterprise Value
- EUR 13.57M
- Total Cash (Recent Filing)
- EUR 2.17M
- Total Debt (Recent Filing)
- EUR 1.34M
- Price to Earnings (P/E)
- ―
- Beta
- 0.87
- Next Earnings
- Nov 16, 2026 (Est.)
- EPS Estimate
- -0.16
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development Progress
Completing dosing moves CDI-988 toward efficacy data and a potentially important clinical inflection point. The randomized, placebo-controlled design tests prevention and treatment, while prior favorable safety findings support continued development of the lead antiviral candidate.
Antiviral Discovery Platform
Cocrystal’s structure-based discovery approach and focus on viral replication provide a defined platform rather than reliance on one isolated asset. Programs spanning norovirus, influenza, coronaviruses and hepatitis C create multiple opportunities for clinical validation and future partnering.
Strategic Financing Support
The $5 million private placement strengthens near-term funding for clinical development and signals continuing support from a longtime investor. Additional capital can help preserve development momentum and extend the company’s ability to generate value from its antiviral pipeline.
Bears Say
Deep Operating Losses
The company remains far from a self-sustaining commercial model: minimal revenue is overwhelmed by research and operating costs. Persistently large losses indicate that future progress depends on successful clinical advancement, partnering, or additional financing before profitability can emerge.
Persistent Cash Burn
Cash generation remains firmly negative, with free cash flow closely tracking net losses and showing that reported losses translate into actual cash outflows. Even with improved burn versus 2024, continued development will require substantial funding before scalable operating inflows are established.
Deteriorated Balance Sheet
Higher leverage combined with a much smaller asset base leaves Cocrystal with a thinner financial buffer while it funds clinical programs. Debt exceeding equity can reduce flexibility, increase dependence on capital markets, and heighten the consequences of delays or unfavorable study outcomes.
8CC FAQ
What was Cocrystal Pharma’s price range in the past 12 months?
What is Cocrystal Pharma’s market cap?
When is Cocrystal Pharma’s upcoming earnings report date?
How were Cocrystal Pharma’s earnings last quarter?
Is Cocrystal Pharma overvalued?
Does Cocrystal Pharma pay dividends?
What is Cocrystal Pharma’s EPS estimate?
How many shares outstanding does Cocrystal Pharma have?
What happened to Cocrystal Pharma’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Cocrystal Pharma?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Cocrystal Pharma
Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses. Its current pipeline includes CC-31244, a non-nucleoside polymerase inhibitor for HCV, which has successfully completed Phase IIa clinical trials. Additionally, CC-42344, a PB2 inhibitor designed to combat influenza, is currently undergoing preclinical development. Cocrystal Pharma is also actively pursuing the development of non-nucleoside polymerase inhibitors to address norovirus infections. The company maintains strategic alliances, including a research and licensing collaboration with Merck Sharp & Dohme Corp. for the discovery and development of proprietary influenza A/B antiviral agents. It also holds a licensing agreement with the Kansas State University Research Foundation, aimed at advancing antiviral compounds for norovirus and coronavirus infections. Furthermore, Cocrystal Pharma engages in drug discovery collaborations with both HitGen and InterX Inc. The company's operations are headquartered in Bothell, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- James E. Sapirstein
- Employees
- 10
- Website
- www.cocrystalpharma.com
- Address
- 19805 North Creek Parkway, Bothell, WA, 98011, US
Cocrystal Pharma (8CC) Earnings & Revenues
8CC Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 4 | 11 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 4 | 0 | 8 |
